NASDAQ · ACTU
Actuate Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ACTU: Nov 12, 2026
Actuate Therapeutics, Inc. Common stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.25.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.15 | $-0.21 | 2 |
| Dec 2026 | $-0.18 | $-0.15 | $-0.20 | 2 |
| Mar 2027 | $-0.16 | $-0.13 | $-0.19 | 2 |
| Jun 2027 | $-0.15 | $-0.12 | $-0.18 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · Quiver Quantitative- Zacks · Oct 12, 11:07 AM EDTTEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in SchizophreniaTeva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
- Zacks · Oct 8, 10:47 AM EDTAbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.
- Zacks · Sep 2, 12:00 PM EDTAll You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to BuyActuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Jul 13, 10:30 PM EDTTop Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus(RTTNews) – Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder Innovations, which recently raised its full
- RTTNews · Apr 15, 6:02 AM EDTActuate Publishes New Positive Phase 2 Data For Elraglusib In Pancreatic Cancer(RTTNews) – Actuate Therapeutics Inc. (ACTU), a clinical-stage biopharmaceutical company, announced the publication of new positive data from the Phase 2 clinical trial for Elraglusib in combination with Gemcitabine-nab-Paclitaxel (GnP) in treating metastatic pancreatic cancers i
- Zacks · Feb 6, 1:58 PM ESTMettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/YMTD beats Q4 estimates as adjusted EPS jumps 8% Y/Y and sales rise to $1.13B, led by solid growth across Laboratory, Industrial and Food Retail.
- RTTNews · Jan 12, 10:19 AM ESTActuate Says Elraglusib Combo Boosts Survival In Metastatic Pancreatic Cancer(RTTNews) – Actuate Therapeutics, Inc. (ACTU) on Monday said it presented new survival and biomarker data from its Phase 2 clinical program evaluating elraglusib for metastatic pancreatic cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO
- Zacks · Dec 24, 12:00 PM ESTActuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Dec 15, 9:17 AM ESTActuate Therapeutics Reports Positive Phase II Data In Salivary Gland Cancers(RTTNews) – Actuate Therapeutics, Inc. (ACTU) on Monday reported positive results from a Phase II study evaluating elraglusib in combination with carboplatin or cisplatin in patients with advanced metastatic salivary gland cancers, including adenoid cystic carcinoma (ACC) and oth
- Zacks · Nov 28, 9:55 AM ESTHow Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the st
- Fintel · Nov 19, 7:02 AM ESTHC Wainwright & Co. Reiterates Actuate Therapeutics (ACTU) Buy RecommendationFintel reports that on November 19, 2025, HC Wainwright & Co. reiterated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a Buy recommendation. Analyst Price Forecast Suggests 318.03% Upside
- Quiver Quantitative · Jul 17, 8:51 AM EDTActuate Therapeutics, Inc. Reports Encouraging Results from Phase 1 Study of Elraglusib in Pediatric Ewing Sarcoma Patients and Plans Phase 2 TrialActuate Therapeutics reports positive Phase 1 results of elraglusib in pediatric Ewing Sarcoma, planning Phase 2 trial.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Actuate Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.